title: Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression.
authors.affiliation: Department of Clinical Pharmacology, Roche Pharmaceutical Research and Early Development, New York City, New York, USA.
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Kamal
authors.affiliation: Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
authors.forename: Ronald
authors.initials: R
authors.lastname: Gieschke
authors.affiliation: Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
authors.forename: Annabelle
authors.initials: A
authors.lastname: Lemenuel-Diot
authors.affiliation: Department of Physics, Ryerson University, Toronto, Ontario, Canada.
authors.forename: Catherine A A
authors.initials: CA
authors.lastname: Beauchemin
authors.affiliation: Monash Institute of Pharmaceutical Sciences, Melbourne, Australia d3 Medicine LLC, Parsippany, New Jersey, USA.
authors.forename: Patrick F
authors.initials: PF
authors.lastname: Smith
authors.affiliation: Monash Institute of Pharmaceutical Sciences, Melbourne, Australia University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York, USA.
authors.forename: Craig R
authors.initials: CR
authors.lastname: Rayner